[
    [
        {
            "time": "",
            "original_text": "速读社丨新基多发性硬化症药物ozanimod遭FDA拒绝",
            "features": {
                "keywords": [
                    "新基",
                    "多发性硬化症",
                    "药物",
                    "ozanimod",
                    "FDA",
                    "拒绝"
                ],
                "sentiment_score": -0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "速读社丨新基多发性硬化症药物ozanimod遭FDA拒绝",
                "Correlation": 9,
                "Sentiment": 2,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        }
    ]
]